<div id="readability-page-1"><p>Sicart Associates LLC grew its stake in  Guardant Health, Inc. (NASDAQ:GH - Free Report) by 39.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 230,083 shares of the company's stock after purchasing an additional 64,628 shares during the quarter. Guardant Health makes up   3.9% of Sicart Associates LLC's holdings, making the stock its 5th biggest position. Sicart Associates LLC owned about 0.18% of Guardant Health worth $14,376,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><div><p><span></span><span>Get <strong>Guardant Health</strong> alerts:</span></p></div><ul><li>4 Healthcare Stocks With Massive Gains—and More to Come</li></ul><p>Several other hedge funds have also recently modified their holdings of the stock. Osaic Holdings Inc. lifted its stake in  Guardant Health by 118.6% in the 2nd quarter. Osaic Holdings Inc. now owns 29,561 shares of the company's stock valued at $1,538,000 after buying an additional 16,039 shares in the last quarter.  State of Wyoming acquired a new position in shares of  Guardant Health during the second quarter valued at approximately $567,000.  Castleark Management LLC purchased a new position in shares of  Guardant Health in the second quarter valued at approximately $6,326,000.  Nikko Asset Management Americas Inc. boosted its stake in shares of  Guardant Health by 49.6% in the second quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company's stock worth $105,623,000 after acquiring an additional 673,438 shares during the last quarter.  Finally, CANADA LIFE ASSURANCE Co increased its position in shares of  Guardant Health by 8.1% during the second quarter. CANADA LIFE ASSURANCE Co now owns 32,485 shares of the company's stock worth $1,694,000 after purchasing an additional 2,421 shares in the last quarter. Institutional investors and hedge funds own  92.60% of the company's stock. </p><h2>Guardant Health Stock Down 2.6%</h2><p>GH stock opened at $100.00 on Wednesday. Guardant Health, Inc. has a 52-week low of $29.91 and a 52-week high of $112.43. The stock has a market cap of $12.60 billion, a price-to-earnings ratio of -31.15 and a beta of 1.58. The business has a fifty day moving average of $90.23 and a two-hundred day moving average of $66.58. </p><ul><li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li></ul><p>Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.09. The business's revenue for the quarter was up 38.5% on a year-over-year basis. During the same period last year, the company earned ($0.88) EPS.  As a group, sell-side analysts anticipate that  Guardant Health, Inc. will post -2.9 EPS for the current year. </p><h2>Analyst Upgrades and Downgrades</h2><p>GH has been the topic of several recent research reports. Guggenheim lifted their target price on shares of Guardant Health from $56.00 to $67.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, September 25th. JPMorgan Chase &amp; Co. boosted their price target on shares of Guardant Health from $90.00 to $120.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday. Citigroup increased their price objective on shares of Guardant Health from $100.00 to $135.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 11th. UBS Group boosted their target price on Guardant Health from $80.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, October 30th. Finally, TD Cowen increased their price target on Guardant Health from $63.00 to $72.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, September 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $94.57.</p><ul><li>3 Fast-Growing Stocks Analysts See Doubling in Price</li></ul><p><b>View Our Latest Research Report on Guardant Health</b></p><h2>Insider Transactions at Guardant Health</h2><p>In other Guardant Health news, CFO Michael Brian Bell sold 80,362 shares of the company's stock in a transaction on Friday, December 5th. The stock was sold at an average price of $103.14, for a total transaction of $8,288,536.68. Following the transaction, the chief financial officer directly owned 28,052 shares in the company, valued at $2,893,283.28. This represents a 74.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CTO Darya Chudova sold 13,664 shares of the firm's stock in a transaction on Monday, December 8th. The stock was sold at an average price of $105.04, for a total value of $1,435,266.56. Following the transaction, the chief technology officer owned 54,480 shares of the company's stock, valued at approximately $5,722,579.20. This represents a 20.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 330,531 shares of company stock worth $34,526,719 in the last three months. Company insiders own  6.10% of the company's stock. </p><h2>Guardant Health Company Profile</h2> (Free Report)<p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Guardant Health</li><li>What is Insider Trading? What You Can Learn from Insider Trading</li><li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li><li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li><li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li><li>Most active stocks: Dollar volume vs share volume</li><li>RTX Surges to Record Highs as Defense Orders Explode</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2><p>Before you consider Guardant Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Sicart Associates LLC increased its stake in Guardant Health, Inc. by 39.1% in Q3, owning 230,083 shares worth $14.38 million. Analysts have raised target prices for Guardant Health, with Guggenheim, JPMorgan, Citigroup, UBS, and TD Cowen all giving 'buy' ratings. The stock has a 'Moderate Buy' average rating with a target price of $94.57. CFO Michael Bell sold 80,362 shares, reducing his ownership by 74.13%.</p>

Guardant Health, Inc. $GH Holdings Boosted by Sicart Associates LLC